Login

Day One Biopharmaceuticals, Inc. 8-K SEC Filings

Filed On Filing
23 Apr 2026 8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more

Section 1.1 Registered Office. The corporation shall maintain a registered office and registered agent in the State of Delaware. The registered office and/or registered agent of the corporation may be changed from time to time by action ...

06 Mar 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This AGREEMENT AND PLAN OF MERGER, dated as of March 6, 2026 (this “Agreement” and, such date, the “Agreement Date”), by and among Servier Pharmaceuticals LLC, a Delaware limited liability company (“Parent”), Servier Detroit Inc., a Dela...

02 Mar 2026 8-K: Regulation FD Disclosure

Exhibit 99.1 Day One Biopharmaceuticals Targeted therapies for people of all ages March 2026

24 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Targeted therapies for people of all ages January 2026 Day One Biopharmaceuticals Exhibit 99.3

06 Jan 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

This Contingent Value Rights Agreement, dated as of January 6, 2026 (this “Agreement”), is entered into by and between Day One Biopharmaceuticals, Inc., a Delaware corporation (“Parent”), and Computershare Inc., a Delaware corporation (“...

24 Nov 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.2 Day One Biopharmaceuticals Targeted therapies for people of all ages November 2025

13 Nov 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Targeted therapies for people of all ages November 2025 Day One Biopharmaceuticals

04 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business

10 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

05 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

OJEMDATM (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase

03 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 2, 2025, Day One Biopharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals:

06 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

OJEMDATM (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024

25 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Achieved Q4 2024 and full year 2024 OJEMDATM (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively

13 Jan 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Exhibit 99.3 Day One Biopharmaceuticals Targeted therapies for people of all ages January 2025

20 Nov 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

30 Oct 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue

30 Jul 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch

30 Jul 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 30, 2024, by and among Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agre...

25 Jul 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support